Explain the role of companion diagnostics in precision medicine and provide an example.

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

Explain the role of companion diagnostics in precision medicine and provide an example.

In precision medicine, companion diagnostics are tests that are developed alongside a specific therapy to identify which patients are most likely to benefit or avoid harm from that treatment. They use a biomarker or molecular signature to predict response, guiding who should receive the drug. This pairing ensures treatment is tailored to individuals rather than given universally, improving effectiveness and minimizing unnecessary toxicity. A classic example is HER2 testing in breast cancer. By assessing HER2 status—through methods like immunohistochemistry or FISH—clinicians identify tumors with HER2 amplification or overexpression. Patients whose tumors are HER2-positive are more likely to respond to trastuzumab, an antibody therapy targeting the HER2 protein, whereas those without this biomarker may derive little benefit and face unnecessary risks. This demonstrates how a diagnostic test directly informs a therapeutic decision. Understanding this role helps explain why companion diagnostics are central to precision medicine: they turn biomarker information into actionable treatment choices, linking a drug to the patients who will benefit from it. In contrast, prognostic tests that predict outcomes regardless of therapy, tests that merely confirm disease, or tests focused on drug metabolism without tying to a specific treatment do not fulfill the same predictive, therapy-specific function.

In precision medicine, companion diagnostics are tests that are developed alongside a specific therapy to identify which patients are most likely to benefit or avoid harm from that treatment. They use a biomarker or molecular signature to predict response, guiding who should receive the drug. This pairing ensures treatment is tailored to individuals rather than given universally, improving effectiveness and minimizing unnecessary toxicity.

A classic example is HER2 testing in breast cancer. By assessing HER2 status—through methods like immunohistochemistry or FISH—clinicians identify tumors with HER2 amplification or overexpression. Patients whose tumors are HER2-positive are more likely to respond to trastuzumab, an antibody therapy targeting the HER2 protein, whereas those without this biomarker may derive little benefit and face unnecessary risks. This demonstrates how a diagnostic test directly informs a therapeutic decision.

Understanding this role helps explain why companion diagnostics are central to precision medicine: they turn biomarker information into actionable treatment choices, linking a drug to the patients who will benefit from it. In contrast, prognostic tests that predict outcomes regardless of therapy, tests that merely confirm disease, or tests focused on drug metabolism without tying to a specific treatment do not fulfill the same predictive, therapy-specific function.

More practice questions